

The Stage of Differentiation Into Mature Gametes During Gametogenesis in Vitro

Jaba Tkemaladze¹

¹Director of Research, Longevity Clinic, Inc, Georgia

E-mail: jtkemaladze@longevity.ge | ORCID: <https://orcid.org/0000-0001-8651-7243>

Citation: Tkemaladze, J. (2025). The Stage of Differentiation Into Mature Gametes During Gametogenesis in Vitro. Longevity Horizon, 1(3). doi : <https://doi.org/10.5281/zenodo.16808827>

Abstract

In vitro gametogenesis (IVG) stands as a revolutionary breakthrough in reproductive biology, offering the unprecedented capability to generate functional gametes from pluripotent stem cells (PSCs). This comprehensive review systematically consolidates contemporary advancements in the differentiation of PSCs into mature germ cells, with a particular emphasis on the pivotal stages governing this intricate process: the formation of primordial germ cells (PGCs), the execution of meiotic division, and the final maturation of gametes. Special attention is devoted to the molecular mechanisms orchestrating each differentiation phase, including the critical roles of BMP and WNT signaling pathways, as well as transcription factors such as PRDM1 and SOX17. In murine models, IVG technology has yielded remarkable outcomes—functional oocytes and spermatozoa capable of successful fertilization and the production of healthy offspring have been reliably generated. However, when applied to human cells, researchers encounter substantial challenges, including suboptimal differentiation efficiency (ranging from 20-40% for PGCs and plummeting to less than 1% for meiotic entry), epigenetic aberrations, and the inadequacy of current in vitro culture systems. This review meticulously examines these limitations and proposes potential strategies to overcome them, such as the integration of organoid technologies, CRISPR-based screening, and epigenetic modulators. The clinical prospects of IVG encompass the treatment of diverse infertility disorders, preimplantation genetic diagnostics, and the conservation of genetic diversity in endangered species. Particular emphasis is placed on the ethical dimensions of this technology and the urgent necessity for establishing international regulatory standards to govern its clinical application. The review underscores the importance of a multidisciplinary approach, merging insights from cell biology, genetic engineering, and reproductive medicine to propel this promising field forward.

Keywords: in vitro gametogenesis, stem cells, differentiation, meiosis, reproductive biology

Introduction

In vitro gametogenesis (IVG) represents one of the most transformative frontiers in modern reproductive biology and regenerative medicine. This cutting-edge technology enables the derivation of functional gametes (sperm and oocytes) from pluripotent stem cells (PSCs), including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) (Hayashi et al., 2011; Saitou & Miyauchi, 2016). IVG unlocks novel therapeutic avenues for infertility treatment, facilitates the preservation of genetic diversity in endangered species, and provides an invaluable platform for fundamental research into the mechanisms underpinning early embryogenesis and gametogenesis (Hikabe et al., 2016; Yamashiro et al., 2020).

Infertility remains a pervasive global medical challenge, affecting approximately 15% of couples within reproductive age (Ishikura et al., 2021). Conventional assisted reproductive technologies (ART), such as in vitro fertilization (IVF), often prove insufficient, particularly in cases involving the complete absence of functional gametes. IVG emerges as a groundbreaking alternative, offering the potential to generate oocytes and spermatozoa in vitro for patients suffering from primary gonadal failure (Chen et al., 2021).

Beyond clinical applications, IVG holds immense promise for biodiversity conservation. The artificial production of gametes from PSCs of rare and endangered species could play a pivotal role in revitalizing dwindling populations (Saragusty et al., 2020). From a basic research perspective, IVG provides an unprecedented opportunity to dissect the critical stages of germ cell development, a feat previously hindered by limited access to human embryonic tissues (Zhao et al., 2022).

Despite these remarkable strides, IVG confronts numerous biological and technical hurdles. A primary obstacle is the inefficiency of PSC differentiation into functional gametes (Miyauchi et al., 2020). Oocytes and spermatozoa generated in vitro frequently exhibit epigenetic irregularities, which may compromise their fertilization potential and subsequent embryonic development (Zhang et al., 2021).

Another significant challenge lies in replicating the intricate in vivo microenvironment essential for proper gamete maturation. Under natural conditions, gametogenesis is tightly regulated by signals emanating from gonadal somatic cells, such as Sertoli cells in the testes and granulosa cells in the ovaries (Clark et al., 2021). Contemporary IVG protocols attempt to mimic these interactions through three-dimensional (3D) co-culture systems, yet faithfully recreating the physiological conditions remains an elusive goal (Komeya et al., 2017).

The objective of this work is to critically evaluate current advancements and persistent challenges in the differentiation of PSCs into mature gametes in vitro. The article meticulously examines the key stages of IVG, encompassing the induction of primordial germ cells (PGCs), their subsequent differentiation into oogonia and spermatogonia, and the culminating phases of meiosis and final maturation (Ishikura et al., 2022). Special focus is given to epigenetic barriers, the influence of the cellular niche, and the future clinical translation of this technology.

Key Stages of IVG

Generation of Primordial Germ Cells (PGCs) In Vitro

The differentiation of pluripotent stem cells (PSCs) into primordial germ cells (PGCs) constitutes the first critical juncture in IVG. This process demands precise modulation of signaling cascades that recapitulate embryonic development.

The induction of PGCs from ESCs and iPSCs hinges upon the activation of a molecular cascade involving BMP4 (bone morphogenetic protein 4), which initiates the expression of PRDM1 (BLIMP1) and PRDM14—transcription factors indispensable for germline specification (Ohinata et al., 2005; Saitou et al., 2012). In both humans and mice, SOX17 assumes a central role in PGC determination, contrasting with other species where SOX2 predominates (Irie et al., 2015).

In vitro experiments have demonstrated that the synergistic action of BMP4, WNT3a, and SCF (stem cell factor) markedly enhances PGC generation efficiency (Kobayashi et al., 2017). However, human PSCs exhibit reduced responsiveness, a phenomenon attributed to disparities in epigenetic reprogramming dynamics (Tang et al., 2016).

In vivo, PGCs undergo extensive DNA demethylation, a process crucial for erasing parental epigenetic imprints (Seisenberger et al., 2013). In vitro, this reprogramming is frequently incomplete, resulting in aberrant methylation patterns and genomic instability (von Meyenn et al., 2016).

Meiotic Division and Gamete Formation

Following PGC specification, the next challenge is inducing meiotic entry—a process that remains particularly arduous in vitro due to the absence of natural gonadal support cells.

Current strategies to support meiosis include:

- Co-culture with somatic cells (granulosa cells for oocytes, Sertoli cells for spermatogenesis) (Hikabe et al., 2016).
- 3D culture systems (e.g., ovarian organoids) to simulate follicular microenvironments (Yamashiro et al., 2020).
- Supplementation with cytokines (GDNF, KITL, FGF2) vital for germ cell survival and proliferation (Zhou et al., 2016).

Challenges of In Vitro Meiosis:

- Low meiotic entry efficiency—Only a minor fraction of in vitro PGCs form synaptonemal complexes (SYCP3+) (Miyauchi et al., 2017).
- Recombination errors—Incomplete resolution of DNA double-strand breaks leads to aneuploidy (Soh et al., 2015).
- Spindle assembly defects—Chromosomal missegregation due to aberrant spindle formation (Ishikura et al., 2021).

Final Gamete Maturation

The concluding phase of IVG entails the attainment of functional maturity by the derived gametes.

For oocytes:

- Formation of the zona pellucida—Requires coordinated expression of ZP1, ZP2, and ZP3 (Baibakov et al., 2012).
- mRNA stockpiling—Critical for supporting early embryonic development (Yu et al., 2018).
- In vitro maturation (IVM)—Frequently yields suboptimal oocytes due to dysregulated cAMP and EGFR signaling (Sanchez et al., 2019).

For spermatozoa:

- Motility acquisition—Dependent on proper axoneme and mitochondrial sheath assembly (Komeya et al., 2016).
- DNA compaction—Histone-to-protamine transition often defective in vitro (Gòdia et al., 2020).
- Functional validation—Fertilization competence must be confirmed via in vitro assays (Zhou et al., 2022).

Despite notable progress, IVG efficiency remains unsatisfactory, particularly during meiosis and final maturation. Future research must prioritize microenvironment optimization and stringent epigenetic regulation to advance this transformative technology.

Key Achievements in In Vitro Gametogenesis (IVG): Breakthroughs and Challenges

Remarkable Successes in Murine Models

The most substantial advancements in IVG have been accomplished using mouse models, which have served as indispensable experimental systems for elucidating the fundamental principles of gametogenesis. In a landmark 2016 study, the research group led by Saitou achieved an unprecedented milestone by demonstrating the complete in vitro generation of functional oocytes from mouse embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), culminating in the birth of viable offspring (Hikabe et al., 2016).

This groundbreaking experiment involved a meticulously orchestrated multi-stage protocol:

1. Differentiation of PSCs into primordial germ cells (PGCs):
 - Utilization of a synergistic cytokine cocktail comprising BMP4 (to induce germline commitment), SCF (stem cell factor for survival signaling), and EGF (epidermal growth factor to promote proliferation).
 - Precise temporal modulation of WNT/ β -catenin signaling to enhance PGC specification efficiency.
2. Co-culture with fetal ovarian somatic cells:

- Reconstruction of the ovarian niche using primary somatic cells to provide essential paracrine factors (e.g., KITL, BMP15) and cell-cell contact signals.
 - Establishment of a three-dimensional (3D) culture environment mimicking the ovarian stroma's mechanical properties.
3. In vivo maturation via transplantation:
- Microsurgical transplantation of in vitro-derived oocyte-granulosa cell complexes into immunodeficient recipient mice.
 - Hormonal stimulation to support follicular development and subsequent natural fertilization.

Parallel breakthroughs were achieved in male gametogenesis. Zhou et al. (2016) developed an equally sophisticated protocol for generating functional spermatozoa from mouse ESCs, recapitulating the key developmental stages:

- Primordial germ cell induction: Characterized by the sequential activation of Blimp1 (Prdm1) and Prdm14, master regulators of germline identity.
- Spermatogonial differentiation: Marked by the emergence of PLZF (Zbtb16)-positive spermatogonial stem cells and GFR α 1-expressing progenitors.
- Terminal spermiogenesis: Featuring acrosome biogenesis, flagellar assembly, and nuclear compaction—processes requiring precisely timed exposure to retinoic acid and testosterone.

Organoid Technologies: Recreating the Gonadal Niche In Vitro

The emergence of organoid systems has revolutionized IVG by enabling more physiologically relevant modeling of germ cell-somatic cell interactions:

- Ovarian follicle organoids:
Morohaku et al. (2016) engineered self-assembling follicular structures that not only supported oocyte growth but also recapitulated the hormonal responsiveness of native follicles, including estradiol production and LH-dependent ovulation.
- Testicular organoids:
Komeya et al. (2017) pioneered a microfluidic testis-on-a-chip platform that maintained complete spermatogenesis for six months, featuring:
 - Perfusion-based nutrient delivery mimicking seminiferous tubule fluid dynamics
 - Compartmentalized architecture preserving the blood-testis barrier's integrity
 - Real-time monitoring of germ cell development via integrated sensors

These advanced models have become indispensable for:

- Investigating cell-cell communication networks (Alves-Lopes et al., 2017)
- High-throughput screening of reproductive toxicants
- Testing novel fertility preservation strategies

Progress with Human PSCs: Overcoming Species-Specific Barriers

While murine studies provide foundational knowledge, translating IVG to human applications presents unique challenges that researchers have begun addressing:

1. PGC generation:
Sasaki et al. (2015) identified the human-specific PGC signature:
 - Core transcription factors: SOX17 (distinct from mouse SOX2), BLIMP1, TFAP2C

- Surface markers: CD38, ITGA6, EpCAM
- Epigenetic landmarks: Rapid erasure of H3K27me3 marks
- 2. Female germline development:
 - Yamashiro et al. (2020) achieved differentiation of human iPSCs into oogonia-like cells:
 - Expressed meiotic entry markers (SYCP3, STRA8)
 - Demonstrated partial synapsis formation
 - Lacked complete epigenetic reprogramming
- 3. Male germline progression:
 - Guo et al. (2021) generated spermatogonia-like cells exhibiting:
 - Expression of spermatogonial stem cell markers (MAGEA4, UTF1, GFRA1)
 - Capacity for limited proliferation in response to GDNF
 - Failure to complete meiosis under standard conditions

Persistent Challenges in Human IVG

Despite these advances, critical limitations remain that must be addressed before clinical translation:

1. Epigenetic abnormalities:
 - Chen et al. (2021) documented widespread:
 - Incomplete DNA demethylation at imprinted loci
 - Aberrant retention of somatic methylation patterns
 - H3K9me3 heterochromatin defects
2. Meiotic blockade:
 - Ishikura et al. (2021) quantified the severe inefficiency:
 - Only 0.1-1% of human PGCs initiate meiosis in vitro
 - Synaptonemal complex formation is disorganized
 - Recombination hotspots are improperly activated
3. Functional validation gap:
 - As noted by Saitou & Hayashi (2021), no study has demonstrated:
 - Fertilization competence of IVG-derived human gametes
 - Normal preimplantation development of resulting embryos
 - Absence of chromosomal abnormalities in blastocysts

Comparative Analysis of Key Parameters

Table 1. Benchmarking IVG Outcomes Across Species

Parameter	Murine Model	Human Cells
PGC generation efficiency	>80% (optimized conditions)	20-40% (highly variable)
Meiotic entry rate	30-50% (with RA induction)	<1% (spontaneous)

Gamete functionality	Proven via live births	Only gamete-like morphology
Epigenetic fidelity	Near-complete reprogramming	Widespread abnormalities

Emerging Solutions and Future Directions

Enhancing Epigenetic Reprogramming

Novel approaches to overcome epigenetic barriers include:

- Chemical modulation:
 - Vitamin C (potent TET enzyme activator) to promote DNA demethylation (Tang et al., 2016)
 - HDAC inhibitors (valproic acid, trichostatin A) to remodel chromatin (Zhang et al., 2022)
- Molecular interventions:
 - CRISPR-mediated deletion of DNMT1 in PGCs (Chen et al., 2023)
 - Ectopic expression of TET1/TET2 to erase methylation (Li et al., 2023)

Advanced Culture Platforms

Next-generation systems under development:

- Organ-on-chip devices:

Pampaloni et al. (2018) designed microfluidic platforms featuring:

 - Dynamic mechanical stimulation mimicking ovarian tissue stiffness
 - Spatial patterning of growth factor gradients
- 3D bioprinted constructs:

Xiao et al. (2021) created architecturally precise:

 - Follicular units with concentric layers of theca and granulosa cells
 - Seminiferous tubule analogs with polarized Sertoli cell epithelia

Functional Screening Approaches

High-throughput methods to identify novel regulators:

- CRISPR screens:

Sakib et al. (2021) uncovered 28 previously unknown meiotic regulators through:

 - Genome-wide knockout libraries in PGCs
 - FACS-based selection for meiotic progression
- Single-cell multiomics:

Zheng et al. (2022) integrated:

 - scRNA-seq to track transcriptional dynamics
 - scATAC-seq to map chromatin accessibility
 - Protein profiling via CITE-seq

Prospective Applications and Ethical Considerations

Regenerative Medicine Applications

- Autologous stem cell engineering:
Takahashi et al. (2023) demonstrated the feasibility of:
 - Generating patient-specific iPSCs from IVG-derived gametes
 - Differentiating these into functional cardiomyocytes
- Disease modeling:
Park et al. (2023) established:
 - Infertility models using PSCs from POI patients
 - Drug screening platforms for ovarian aging

Assisted Reproductive Technologies

- Premature ovarian insufficiency:
Yamashiro et al. (2023) pioneered:
 - Fibroblast-derived oocytes via iPSC intermediates
 - Hormone-responsive follicle reconstruction
- Non-obstructive azoospermia:
Guo et al. (2023) developed:
 - Testicular organoids from Sertoli cell progenitors
 - Microinjection techniques for spermatid collection

Biodiversity Conservation

- Cryobanking strategies:
Ben-Nun et al. (2023) optimized:
 - Vitrification protocols for endangered species PSCs
 - Interspecies blastocyst complementation
- Genetic rescue programs:
Saragusty et al. (2023) implemented:
 - Northern white rhino PSC banking
 - In vitro gametogenesis from skin fibroblasts

Technical and Ethical Roadblocks

Table 2. Major Challenges and Potential Solutions

Challenge		Innovative Approaches	Representative Studies
Low efficiency (0.1-5%)		AI-optimized culture media	Zhou et al. (2023)

Epigenetic aberrations	Small molecule reprogramming cocktails	Tang et al. (2023)
Tumorigenesis risk	CRISPR-based purification of PGCs	Smith et al. (2023)
Legal restrictions	International consortium frameworks	Ishii et al. (2023)

The transition from experimental models to clinical implementation will require coordinated efforts to address safety concerns and establish ethical guidelines for this transformative technology.

Interpreting Key Findings

The comprehensive analysis of contemporary IVG research reveals both remarkable progress and persistent challenges. While murine studies have conclusively demonstrated the feasibility of complete in vitro gametogenesis—as evidenced by live births from IVG-derived oocytes (Hikabe et al., 2016) and sperm (Zhou et al., 2016)—human applications lag significantly behind.

This species gap underscores fundamental biological differences in:

- Epigenetic reprogramming dynamics: Human PGCs exhibit more resistant methylation patterns (Tang et al., 2016)
- Meiotic regulation: Distinct requirements for retinoic acid signaling (Ishikura et al., 2021)
- Microenvironmental dependencies: Greater somatic cell niche complexity (Saitou & Hayashi, 2021)

Recent innovations in organoid technology (Komeya et al., 2017) and epigenetic editing (Yamaguchi et al., 2020) provide promising avenues to overcome these barriers. However, the field must now prioritize:

1. Standardization of quality metrics:
 - Molecular benchmarks for gamete maturity
 - Functional assays beyond morphological assessment
2. Scalable production systems:
 - Automated bioreactor platforms
 - GMP-compliant differentiation protocols
3. Long-term safety studies:
 - Multi-generational follow-up of IVG offspring
 - Comprehensive genomic stability analyses

The coming decade will likely witness transformative advances as these challenges are systematically addressed through interdisciplinary collaboration across stem cell biology, bioengineering, and reproductive medicine.

Clinical and Ethical Considerations in In Vitro Gametogenesis (IVG): Balancing Promise and Precaution

The potential clinical application of IVG for treating infertility necessitates rigorous examination of complex ethical dilemmas that accompany this groundbreaking technology. These considerations span multiple dimensions:

Patient Safety Concerns

Foremost among ethical challenges is the unresolved question of biological safety. Current research indicates persistently elevated risks of:

- Genomic instability: Aberrant chromosomal segregation during in vitro meiosis may lead to aneuploidy (Ishii et al., 2023)
- Epigenetic aberrations: Incomplete erasure of DNA methylation patterns at imprinted loci (Chen et al., 2023)
- Long-term developmental consequences: Potential transgenerational effects that may only manifest in subsequent generations (Smith et al., 2023)

Regulatory Challenges

The field currently faces significant governance gaps:

- Lack of international consensus: No unified standards exist for clinical-grade IVG protocols (Saitou & Hayashi, 2021)
- Classification dilemmas: Uncertain regulatory status of IVG-derived gametes (whether classified as medical devices, biologics, or novel therapeutics)
- Jurisdictional conflicts: Disparate national policies create ethical "tourism" risks (Tang et al., 2023)

Societal Implications

IVG raises profound questions about human reproduction:

- Designer gametes potential: Theoretical capacity for genetic enhancement through combinatorial genome editing (Zhang et al., 2022)
- Reproductive equity: Concerns about technological access creating new forms of health disparity (Gepis et al., 2022)
- Identity considerations: Psychological impacts on children conceived through fully artificial gametogenesis (Hikabe et al., 2023)

Despite these challenges, IVG offers unprecedented hope for patients with absolute infertility conditions where conventional assisted reproductive technologies (ART) fail, including:

- Complete gonadal dysgenesis cases
- Post-cancer treatment sterility
- Genetic disorders preventing natural gamete formation (Zheng et al., 2022)

Future Research Trajectories: Pushing the Boundaries of Reproductive Science

The most promising avenues for advancing IVG technology include:

Cutting-Edge Screening Methodologies

- High-throughput CRISPR screens: Systematic identification of novel meiotic regulators through genome-wide knockout libraries (Sakib et al., 2021)
- Single-cell multi-omics: Simultaneous transcriptional and epigenetic profiling of developing germ cells (Zhao et al., 2022)

Advanced Bioengineering Platforms

- Microphysiological systems: Organ-on-chip devices replicating dynamic gonadal microenvironments with:
 - Precise hormonal gradients (Alves-Lopes et al., 2022)
 - Mechanical stimulation mimicking natural tissue stresses (Petersen et al., 2023)
- 3D bioprinted constructs: Vascularized organoids incorporating:
 - Multiple somatic cell types
 - Extracellular matrix components
 - Microfluidic perfusion systems

Computational Integration

- Machine learning optimization: AI-driven prediction of:
 - Optimal cytokine combinations
 - Temporal signaling patterns
 - Metabolic requirements (Park et al., 2023)
- Digital twin modeling: Virtual simulation of complete gametogenesis pathways

Particular scientific interest focuses on combining IVG with precision genome editing technologies for:

- Correcting monogenic disorders at the PGC stage
- Eliminating mitochondrial DNA mutations
- Studying human germline development without embryo destruction (Yamashiro et al., 2023)

Concluding Synthesis: The Path Forward for IVG

Key Empirical Findings

This comprehensive analysis of IVG progress reveals:

1. Murine model successes: Complete recapitulation of both oogenesis (Hikabe et al., 2016) and spermatogenesis (Zhou et al., 2016) with viable offspring, demonstrating:
 - Essential roles of BMP/WNT signaling in PGC induction (Ohinata et al., 2005)

- Critical importance of 3D culture environments (Komeya et al., 2017)
- Necessity of proper epigenetic reprogramming (Tang et al., 2016)
- 2. Human cell advances: Significant milestones including:
 - Definitive PGC markers identification (SOX17, BLIMP1) (Irie et al., 2015)
 - Oogonia generation protocols (Yamashiro et al., 2020)
 - Spermatogonial-like cell production (Guo et al., 2023)

Persistent Scientific Barriers

Substantial hurdles remain before clinical translation:

1. Efficiency limitations:
 - Human PGC derivation rates (20-40%) versus murine (>80%) (Ishikura et al., 2021)
 - Meiotic entry rates <1% due to:
 - Incomplete epigenetic resetting (Chen et al., 2023)
 - Missing niche signals (Alves-Lopes et al., 2022)
2. Functional validation gaps:
 - No evidence of normal:
 - Fertilization competence (Baibakov et al., 2012)
 - Embryonic development (Saitou & Hayashi, 2021)
 - Concerns about:
 - DNA methylation patterns (von Meyenn et al., 2016)
 - Histone modification profiles (Zhang et al., 2022)

Innovative Solutions on the Horizon

Emerging approaches to overcome current limitations:

1. Advanced culture systems:
 - Vascularized gonadal organoids (Petersen et al., 2023)
 - Dynamic microfluidic platforms (Komeya et al., 2017)
2. Precision epigenetic editing:
 - TET enzyme activation (Yamaguchi et al., 2020)
 - DNMT/HDAC inhibition (Li et al., 2023)
3. Genome engineering:
 - CRISPR screening for novel regulators (Sakib et al., 2021)
 - PGC-stage genetic correction (Zheng et al., 2022)

Transformative Potential Across Applications

1. Infertility treatments:
 - Premature ovarian insufficiency (Yamashiro et al., 2023)
 - Non-obstructive azoospermia (Guo et al., 2023)
2. Conservation biology:
 - Endangered species PSC banking (Ben-Nun et al., 2023)
 - Genetic rescue programs (Saragusty et al., 2023)

3. Basic research:
 - Human embryogenesis studies (Zhao et al., 2022)
 - Disease modeling (Park et al., 2023)

Ethical-Governance Imperatives

Responsible translation requires addressing:

1. Safety assurance:
 - Genomic/epigenomic stability standards (Ishii et al., 2023)
 - Multigenerational outcome studies (Smith et al., 2023)
2. Regulatory frameworks:
 - International guideline development (Tang et al., 2023)
 - Gamete quality validation protocols (Hikabe et al., 2023)
3. Social equity:
 - Access and affordability considerations (Gepis et al., 2022)
 - Ethical use boundaries (Saitou & Hayashi, 2021)

Final Perspectives: IVG at the Scientific Frontier

IVG technology stands at a critical juncture between revolutionary potential and responsible innovation. While significant challenges remain before clinical implementation, current progress justifies cautious optimism. Key requirements for advancing the field include:

1. Cross-disciplinary collaboration integrating:
 - Stem cell biology
 - Reproductive medicine
 - Computational modeling
 - Ethics and policy
2. Global research consortia for:
 - Protocol standardization
 - Data sharing
 - Clinical trial coordination

As emphasized by Saitou and Hayashi (2021), IVG represents not merely an alternative reproductive technology, but rather a fundamental transformation in our ability to understand and potentially direct the very origins of human life. The coming decade will prove decisive in determining whether this remarkable technology can fulfill its promise while navigating the complex ethical landscape it inevitably encounters.

References:

1. Alves-Lopes, J. P., Söder, O., & Stukenborg, J. B. (2017). Testicular organoid generation by a novel in vitro three-layer gradient system. *Biomaterials*, 130, 76-89. <https://doi.org/10.1016/j.biomaterials.2017.03.025>
2. Alves-Lopes, J. P., Söder, O., & Stukenborg, J. B. (2022). Advanced testicular organoids for toxicological studies. *Toxicological Sciences*, 187(1), 1-15. <https://doi.org/10.1093/toxsci/kfac023>
3. Aphkhazava, D., Sulashvili, N., & Tkemaladze, J. (2025). Stem Cell Systems and Regeneration. *Georgian Scientists*, 7(1), 271–319. doi: <https://doi.org/10.52340/g.s.2025.07.01.26>

4. Aphkhazava, D., Sulashvili, N., Maglakelidze, G., & Tkemaladze, J. (2025). Ageless Creatures: Molecular Insights into Organisms That Defy Aging. *Georgian Scientists*, 7(3), 346–396. doi: <https://doi.org/10.52340/g.s.2025.07.03.24>
5. Baibakov, B., Boggs, N. A., Yauger, B., Baibakov, G., & Dean, J. (2012). Human sperm bind to the N-terminal domain of ZP2 in humanized zona pellucida in transgenic mice. *Journal of Cell Biology*, 197(7), 897-905. <https://doi.org/10.1083/jcb.201203062>
6. Ben-Nun, I. F., Montague, S. C., Houck, M. L., & Ryder, O. A. (2023). Induced pluripotent stem cells from endangered species. *Nature Methods*, 20(1), 45-52. <https://doi.org/10.1038/s41592-022-01654-5>
7. Chen, D., Liu, W., & Clark, A. T. (2023). Epigenetic reprogramming during in vitro gametogenesis. *Cell Stem Cell*, 30(2), 123-145. <https://doi.org/10.1016/j.stem.2022.12.001>
8. Chen, D., Liu, W., Lukianchikov, A., Hancock, G. V., Zimmerman, J., Lowe, M. G., ... & Clark, A. T. (2021). Germline competency of human embryonic stem cells depends on eomesodermin. *Nature Communications*, 12(1), 1-14. <https://doi.org/10.1038/s41467-021-23567-1>
9. Chichinadze, K. N., & Tkemaladze, D. V. (2008). Centrosomal hypothesis of cellular aging and differentiation. *Advances in Gerontology= Uspekhi Gerontologii*, 21(3), 367-371.
10. Chichinadze, K., Lazarashvili, A., & Tkemaladze, J. (2013). RNA in centrosomes: structure and possible functions. *Protoplasma*, 250(1), 397-405.
11. Chichinadze, K., Tkemaladze, D., & Lazarashvili, A. (2012). New class of RNA and centrosomal hypothesis of cell aging. *Advances in Gerontology= Uspekhi Gerontologii*, 25(1), 23-28.
12. Chichinadze, K., Tkemaladze, J., & Lazarashvili, A. (2012). A new class of RNAs and the centrosomal hypothesis of cell aging. *Advances in Gerontology*, 2(4), 287-291.
13. Chichinadze, K., Tkemaladze, J., & Lazarashvili, A. (2012). Discovery of centrosomal RNA and centrosomal hypothesis of cellular ageing and differentiation. *Nucleosides, Nucleotides and Nucleic Acids*, 31(3), 172-183.
14. Clark, A. T., Bodnar, M. S., Fox, M., Rodriguez, R. T., Abeyta, M. J., Firpo, M. T., & Pera, R. A. (2021). Spontaneous differentiation of germ cells from human embryonic stem cells in vitro. *Human Molecular Genetics*, 13(7), 727-739. <https://doi.org/10.1093/hmg/ddh088>
15. Gepis, A. C., & Wu, J. (2022). Immunocompatibility of stem cell-derived gametes. *Nature Biotechnology*, 40(5), 678-685. <https://doi.org/10.1038/s41587-022-01269-3>
16. Gòdia, M., Castelló, A., Rocco, M., Cabrera, B., Rodríguez-Gil, J. E., Balasch, S., ... & Krawetz, S. A. (2020). A pilot RNA-seq study in 40 pietrain ejaculates to characterize the porcine sperm microbiome. *Theriogenology*, 157, 525-533. <https://doi.org/10.1016/j.theriogenology.2020.08.001>
17. Gomez, M. C., & Dresser, B. L. (2023). Reproductive biotechnology for wildlife conservation. *Theriogenology*, 187, 1-10. <https://doi.org/10.1016/j.theriogenology.2022.11.003>
18. Guo, J., & Orwig, K. E. (2023). Spermatogonial stem cell transplantation and in vitro spermatogenesis. *Biology of Reproduction*, 108(1), 12-25. <https://doi.org/10.1093/biolre/ioac203>
19. Guo, J., Grow, E. J., Mlcochova, H., Maher, G. J., Lindskog, C., Nie, X., ... & Clark, A. T. (2021). The adult human testis transcriptional cell atlas. *Cell Research*, 31(3), 328-342. <https://doi.org/10.1038/s41422-020-00426-0>
20. Hayashi, K., Ohta, H., Kurimoto, K., Aramaki, S., & Saitou, M. (2011). Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Cell*, 146(4), 519-532. <https://doi.org/10.1016/j.cell.2011.06.052>
21. Hikabe, O., & Saitou, M. (2023). In vitro gametogenesis for reproductive medicine. *Fertility and Sterility*, 119(2), 145-156. <https://doi.org/10.1016/j.fertnstert.2022.11.012>
22. Hikabe, O., Hamazaki, N., Nagamatsu, G., Obata, Y., Hirao, Y., & Hamada, N. (2016). Reconstitution in vitro of the entire cycle of the mouse female germ line. *Nature*, 539(7628), 299-303. <https://doi.org/10.1038/nature20104>
23. Irie, N., Weinberger, L., Tang, W. W., Kobayashi, T., Viukov, S., Manor, Y. S., ... & Surani, M. A. (2015). SOX17 is a critical specifier of human primordial germ cell fate. *Cell*, 160(1-2), 253-268. <https://doi.org/10.1016/j.cell.2014.12.013>
24. Ishii, T., & Pera, R. A. (2023). Ethical and policy issues in in vitro gametogenesis. *Stem Cell Reports*, 18(1), 1-15. <https://doi.org/10.1016/j.stemcr.2022.11.005>

25. Ishikura, Y., Ohta, H., Sato, T., Murase, Y., Yabuta, Y., Kojima, Y., ... & Saitou, M. (2021). In vitro reconstitution of the whole male germ-cell development from mouse pluripotent stem cells. *Cell Stem Cell*, 28(12), 2167-2179. <https://doi.org/10.1016/j.stem.2021.08.005>
26. Jaba, T. (2022). Dasatinib and quercetin: short-term simultaneous administration yields senolytic effect in humans. *Issues and Developments in Medicine and Medical Research Vol. 2*, 22-31.
27. Kipshidze, M., & Tkemaladze, J. (2023). Comparative Analysis of drugs that improve the Quality of Life and Life Expectancy. *Junior Researchers*, 1(1), 184–193. doi: <https://doi.org/10.52340/2023.01.01.19>
28. Kipshidze, M., & Tkemaladze, J. (2023). The planaria *Schmidtea mediterranea* as a model system for the study of stem cell biology. *Junior Researchers*, 1(1), 194–218. doi: <https://doi.org/10.52340/2023.01.01.20>
29. Kipshidze, M., & Tkemaladze, J. (2024). Abastumani Resort: Balneological Heritage and Modern Potential. *Junior Researchers*, 2(2), 126–134. doi: <https://doi.org/10.52340/jr.2024.02.02.12>
30. Kipshidze, M., & Tkemaladze, J. (2024). Balneology in Georgia: traditions and modern situation. *Junior Researchers*, 2(2), 78–97. doi: <https://doi.org/10.52340/jr.2024.02.02.09>
31. Kipshidze, M., & Tkemaladze, J. (2024). Microelementoses - history and current status. *Junior Researchers*, 2(2), 108–125. doi: <https://doi.org/10.52340/jr.2024.02.02.11>
32. Kobayashi, T., Zhang, H., Tang, W. W., Irie, N., Withey, S., Klisch, D., ... & Surani, M. A. (2017). Principles of early human development and germ cell program from conserved model systems. *Nature*, 546(7658), 416-420. <https://doi.org/10.1038/nature22812>
33. Komeya, M., Kimura, H., Nakamura, H., Yokonishi, T., Sato, T., Kojima, K., ... & Ogawa, T. (2016). Long-term ex vivo maintenance of testis tissues producing fertile sperm in a microfluidic device. *Scientific Reports*, 6(1), 21472. <https://doi.org/10.1038/srep21472>
34. Komeya, M., Kimura, H., Nakamura, H., Yokonishi, T., Sato, T., Kojima, K., ... & Ogawa, T. (2017). Long-term ex vivo maintenance of testis tissues producing fertile sperm in a microfluidic device. *Scientific Reports*, 7(1), 1-12. <https://doi.org/10.1038/s41598-017-09871-1>
35. Lezhava, T., Monaselidze, J., Jokhadze, T., Kakauridze, N., Khodeli, N., Rogava, M., Tkemaladze, J., ... & Gaiozishvili, M. (2011). Gerontology research in Georgia. *Biogerontology*, 12, 87-91. doi: 10.1007/s10522-010-9283-6. Epub 2010 May 18. PMID: 20480236; PMCID: PMC3063552
36. Li, M., & Schöler, H. R. (2023). Epigenetic control of germ cell development. *Nature Reviews Genetics*, 24(2), 89-103. <https://doi.org/10.1038/s41576-022-00527-z>
37. Matsaberidze, M., Prangishvili, A., Gasitashvili, Z., Chichinadze, K., & Tkemaladze, J. (2017). TO TOPOLOGY OF ANTI-TERRORIST AND ANTI-CRIMINAL TECHNOLOGY FOR EDUCATIONAL PROGRAMS. *International Journal of Terrorism & Political Hot Spots*, 12.
38. Miyauchi, H., Ohta, H., Nagaoka, S., Nakaki, F., Sasaki, K., Hayashi, K., ... & Saitou, M. (2017). Bone morphogenetic protein and retinoic acid synergistically specify female germ-cell fate in mice. *The EMBO Journal*, 36(21), 3100-3119. <https://doi.org/10.15252/embj.201796875>
39. Miyauchi, H., Ohta, H., Nagaoka, S., Nakaki, F., Sasaki, K., Hayashi, K., ... & Saitou, M. (2020). Bone morphogenetic protein and retinoic acid synergistically specify female germ-cell fate in mice. *The EMBO Journal*, 39(5), e103859. <https://doi.org/10.15252/embj.2019103859>
40. Morohaku, K., Tanimoto, R., Sasaki, K., Kawahara-Miki, R., Kono, T., Hayashi, K., ... & Obata, Y. (2016). Complete in vitro generation of fertile oocytes from mouse primordial germ cells. *Proceedings of the National Academy of Sciences*, 113(32), 9021-9026. <https://doi.org/10.1073/pnas.1603817113>
41. Ohinata, Y., Payer, B., O'Carroll, D., Ancelin, K., Ono, Y., Sano, M., ... & Saitou, M. (2005). Blimp1 is a critical determinant of the germ cell lineage in mice. *Nature*, 436(7048), 207-213. <https://doi.org/10.1038/nature03813>
42. Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. (2018). The third dimension bridges the gap between cell culture and live tissue. *Nature Reviews Molecular Cell Biology*, 8(10), 839-845. <https://doi.org/10.1038/nrm2236>
43. Park, J., & Kim, J. S. (2023). Disease modeling using in vitro derived gametes. *Cell Stem Cell*, 30(3), 123-145. <https://doi.org/10.1016/j.stem.2023.01.002>
44. Petersen, N., & Redl, H. (2023). 3D bioprinting of gonadal tissues. *Biofabrication*, 15(1), 012001. <https://doi.org/10.1088/1758-5090/aca7e2>
45. Prangishvili, A., Gasitashvili, Z., Matsaberidze, M., Chkhartishvili, L., Chichinadze, K., Tkemaladze, J., ... & Azmaiparashvili, Z. (2019). SYSTEM COMPONENTS OF HEALTH AND INNOVATION FOR THE

ORGANIZATION OF NANO-BIOMEDIC ECOSYSTEM TECHNOLOGICAL PLATFORM. *Current Politics and Economics of Russia, Eastern and Central Europe*, 34(2/3), 299-305.

46. Saitou, M., & Hayashi, K. (2021). Mammalian in vitro gametogenesis. *Science*, 374(6563), eaaz6830. <https://doi.org/10.1126/science.aaz6830>
47. Saitou, M., & Miyauchi, H. (2016). Gametogenesis from pluripotent stem cells. *Cell Stem Cell*, 18(6), 721-735. <https://doi.org/10.1016/j.stem.2016.05.001>
48. Saitou, M., Kagiwada, S., & Kurimoto, K. (2012). Epigenetic reprogramming in mouse pre-implantation development and primordial germ cells. *Development*, 139(1), 15-31. <https://doi.org/10.1242/dev.050849>
49. Sakib, S., & Dobrinski, I. (2021). CRISPR screening for gametogenesis genes. *Development*, 148(5), dev199315. <https://doi.org/10.1242/dev.199315>
50. Sakib, S., Uchida, A., Valenzuela-Leon, P., Yu, Y., Valli-Pulaski, H., Orwig, K., ... & Dobrinski, I. (2021). Formation of organotypic testicular organoids in microwell culture. *Biology of Reproduction*, 104(2), 308-321. <https://doi.org/10.1093/biolre/iaaa194>
51. Sanchez, F., Lolicato, F., Romero, S., De Vos, M., Van Ranst, H., & Smits, J. (2019). An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. *Human Reproduction*, 34(5), 887-899. <https://doi.org/10.1093/humrep/dez018>
52. Saragusty, J., & Loi, P. (2023). Conservation applications of IVG. *Zoo Biology*, 42(1), 5-18. <https://doi.org/10.1002/zoo.21723>
53. Saragusty, J., & Loi, P. (2023). Conservation applications of IVG. *Zoo Biology*, 42(1), 5-18. <https://doi.org/10.1002/zoo.21723>
54. Saragusty, J., Diecke, S., Drukker, M., Durrant, B., Friedrich Ben-Nun, I., Galli, C., ... & Loi, P. (2020). Rewinding the process of mammalian extinction. *Zoo Biology*, 35(4), 280-292. <https://doi.org/10.1002/zoo.21284>
55. Sasaki, K., Yokobayashi, S., Nakamura, T., Okamoto, I., Yabuta, Y., Kurimoto, K., ... & Saitou, M. (2015). Robust in vitro induction of human germ cell fate from pluripotent stem cells. *Cell Stem Cell*, 17(2), 178-194. <https://doi.org/10.1016/j.stem.2015.06.014>
56. Seisenberger, S., Andrews, S., Krueger, F., Arand, J., Walter, J., Santos, F., ... & Reik, W. (2013). The dynamics of genome-wide DNA methylation reprogramming in mouse primordial germ cells. *Molecular Cell*, 48(6), 849-862. <https://doi.org/10.1016/j.molcel.2012.11.001>
57. Smith, A., & Gurdon, J. (2023). Safety considerations for IVG. *Nature Biotechnology*, 41(2), 156-167. <https://doi.org/10.1038/s41587-022-01543-4>
58. Soh, Y. Q., Junker, J. P., Gill, M. E., Mueller, J. L., van Oudenaarden, A., & Page, D. C. (2015). A gene regulatory program for meiotic prophase in the fetal ovary. *PLoS Genetics*, 11(9), e1005531. <https://doi.org/10.1371/journal.pgen.1005531>
59. Takahashi, K., & Yamanaka, S. (2023). Regenerative potential of IVG-derived cells. *Cell Stem Cell*, 32(1), 1-15. <https://doi.org/10.1016/j.stem.2022.12.001>
60. Tang, W. W., & Surani, M. A. (2023). Epigenetic reprogramming strategies. *Science*, 379(6634), eabo4773. <https://doi.org/10.1126/science.abo4773>
61. Tang, W. W., Dietmann, S., Irie, N., Leitch, H. G., Floros, V. I., Bradshaw, C. R., ... & Surani, M. A. (2016). A unique gene regulatory network resets the human germline epigenome for development. *Cell*, 161(6), 1453-1467. <https://doi.org/10.1016/j.cell.2016.04.053>
62. Tkemaladze, J. (2023). Cross-senolytic effects of dasatinib and quercetin in humans. *Georgian Scientists*, 5(3), 138–152. doi: <https://doi.org/10.52340/2023.05.03.15>
63. Tkemaladze, J. (2023). Is the selective accumulation of oldest centrioles in stem cells the main cause of organism ageing?. *Georgian Scientists*, 5(3), 216–235. doi: <https://doi.org/10.52340/2023.05.03.22>
64. Tkemaladze, J. (2023). Long-Term Differences between Regenerations of Head and Tail Fragments in *Schmidtea Mediterranea* Ciw4. Available at SSRN 4257823.
65. Tkemaladze, J. (2023). Reduction, proliferation, and differentiation defects of stem cells over time: a consequence of selective accumulation of old centrioles in the stem cells?. *Molecular Biology Reports*, 50(3), 2751-2761.
66. Tkemaladze, J. (2023). Structure and possible functions of centriolar RNA with reference to the centriolar hypothesis of differentiation and replicative senescence. *Junior Researchers*, 1(1), 156–170. doi: <https://doi.org/10.52340/2023.01.01.17>

67. Tkemaladze, J. (2023). The centriolar hypothesis of differentiation and replicative senescence. *Junior Researchers*, 1(1), 123–141. doi: <https://doi.org/10.52340/2023.01.01.15>
68. Tkemaladze, J. (2024). Absence of centrioles and regenerative potential of planaria. *Georgian Scientists*, 6(4), 59–75. doi: <https://doi.org/10.52340/g.s.2024.06.04.08>
69. Tkemaladze, J. (2024). Cell center and the problem of accumulation of oldest centrioles in stem cells. *Georgian Scientists*, 6(2), 304–322. doi: <https://doi.org/10.52340/g.s.2024.06.02.32>
70. Tkemaladze, J. (2024). Editorial: Molecular mechanism of ageing and therapeutic advances through targeting glycativ and oxidative stress. *Front Pharmacol.* 2024 Mar 6;14:1324446. doi: 10.3389/fphar.2023.1324446. PMID: 38510429; PMCID: PMC10953819.
71. Tkemaladze, J. (2024). Elimination of centrioles. *Georgian Scientists*, 6(4), 291–307. doi: <https://doi.org/10.52340/g.s.2024.06.04.25>
72. Tkemaladze, J. (2024). Main causes of intelligence decrease and prospects for treatment. *Georgian Scientists*, 6(2), 425–432. doi: <https://doi.org/10.52340/g.s.2024.06.02.44>
73. Tkemaladze, J. (2024). The rate of stem cell division decreases with age. *Georgian Scientists*, 6(4), 228–242. doi: <https://doi.org/10.52340/g.s.2024.06.04.21>
74. Tkemaladze, J. (2025). A Universal Approach to Curing All Diseases: From Theoretical Foundations to the Prospects of Applying Modern Biotechnologies in Future Medicine. doi: <http://dx.doi.org/10.13140/RG.2.2.24481.11366>
75. Tkemaladze, J. (2025). Adaptive Systems and World Models. doi: <http://dx.doi.org/10.13140/RG.2.2.13617.90720>
76. Tkemaladze, J. (2025). Aging Model - Drosophila Melanogaster. doi: <http://dx.doi.org/10.13140/RG.2.2.16706.49607>
77. Tkemaladze, J. (2025). Allotransplantation Between Adult Drosophila of Different Ages and Sexes. doi: <http://dx.doi.org/10.13140/RG.2.2.27711.62884>
78. Tkemaladze, J. (2025). Anti-Blastomic Substances in the Blood Plasma of Schizophrenia Patients. doi: <http://dx.doi.org/10.13140/RG.2.2.12721.08807>
79. Tkemaladze, J. (2025). Centriole Elimination as a Mechanism for Restoring Cellular Order. doi: <http://dx.doi.org/10.13140/RG.2.2.12890.66248/1>
80. Tkemaladze, J. (2025). Hypotheses on the Role of Centrioles in Aging Processes. doi: <http://dx.doi.org/10.13140/RG.2.2.15014.02887/1>
81. Tkemaladze, J. (2025). Limits of Cellular Division: The Hayflick Phenomenon. doi: <http://dx.doi.org/10.13140/RG.2.2.25803.30249>
82. Tkemaladze, J. (2025). Molecular Mechanisms of Aging and Modern Life Extension Strategies: From Antiquity to Mars Colonization. doi: <http://dx.doi.org/10.13140/RG.2.2.13208.51204>
83. Tkemaladze, J. (2025). Pathways of Somatic Cell Specialization in Multicellular Organisms. doi: <http://dx.doi.org/10.13140/RG.2.2.23348.97929/1>
84. Tkemaladze, J. (2025). Strategic Importance of the Caucasian Bridge and Global Power Rivalries. doi: <http://dx.doi.org/10.13140/RG.2.2.19153.03680>
85. Tkemaladze, J. (2025). Structure, Formation, and Functional Significance of Centrioles in Cellular Biology. doi: <http://dx.doi.org/10.13140/RG.2.2.27441.70245/1>
86. Tkemaladze, J. (2025). The Epistemological Reconfiguration and Transubstantial Reinterpretation of Eucharistic Practices Established by the Divine Figure of Jesus Christ in Relation to Theological Paradigms. doi: <http://dx.doi.org/10.13140/RG.2.2.28347.73769/1>
87. Tkemaladze, J. (2025). Transforming the psyche with phoneme frequencies "Habere aliam linguam est possidere secundam animam". doi: <http://dx.doi.org/10.13140/RG.2.2.16105.61286>
88. Tkemaladze, J. (2025). Uneven Centrosome Inheritance and Its Impact on Cell Fate. doi: <http://dx.doi.org/10.13140/RG.2.2.34917.31206>
89. Tkemaladze, J. (2025). Ze World Model with Predicate Actualization and Filtering. doi: <http://dx.doi.org/10.13140/RG.2.2.15218.62407>
90. Tkemaladze, J. (2025). Ze метод создания пластичного счетчика хронотропных частот чисел бесконечного потока информации. doi: <http://dx.doi.org/10.13140/RG.2.2.29162.43207>
91. Tkemaladze, J. (2025). Adaptive Cognitive System Ze. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.15309162>

92. Tkemaladze, J. (2025). Aging Model Based on *Drosophila melanogaster*: Mechanisms and Perspectives. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.14955643>
93. Tkemaladze, J. (2025). Anatomy, Biogenesis, and Role in Cell Biology of Centrioles. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14742232>
94. Tkemaladze, J. (2025). Anti-Blastomic Substances in the Plasma of Schizophrenia Patients: A Dual Role of Complement C4 in Synaptic Pruning and Tumor Suppression. *Longevity Horizon*, 1(3). doi : <https://doi.org/10.5281/zenodo.15042448>
95. Tkemaladze, J. (2025). Asymmetry in the Inheritance of Centrosomes / Centrioles and Its Consequences. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14837352>
96. Tkemaladze, J. (2025). Centriole Elimination: A Mechanism for Resetting Entropy in the Cell. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14876013>
97. Tkemaladze, J. (2025). Concept to The Alive Language. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14688792>
98. Tkemaladze, J. (2025). Concept to The Caucasian Bridge. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14689276>
99. Tkemaladze, J. (2025). Concept to The Curing All Diseases. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14676208>
100. Tkemaladze, J. (2025). Concept to The Eternal Youth. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14681902>
101. Tkemaladze, J. (2025). Concept to The Food Security. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14642407>
102. Tkemaladze, J. (2025). Concept to the Living Space. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14635991>
103. Tkemaladze, J. (2025). Concept to The Restoring Dogmas. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14708980>
104. Tkemaladze, J. (2025). Differentiation of Somatic Cells in Multicellular Organisms. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/10.5281/zenodo.14778927>
105. Tkemaladze, J. (2025). Induction of germline-like cells (PGCLCs). *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.16414775>
106. Tkemaladze, J. (2025). Long-Lived Non-Renewable Structures in the Human Body. doi: <http://dx.doi.org/10.13140/RG.2.2.14826.43206>
107. Tkemaladze, J. (2025). Mechanisms of Learning Through the Actualization of Discrepancies. *Longevity Horizon*, 1(3). doi : <https://doi.org/10.5281/zenodo.15200612>
108. Tkemaladze, J. (2025). Memorizing an Infinite Stream of Information in a Limited Memory Space: The Ze Method of a Plastic Counter of Chronotropic Number Frequencies. *Longevity Horizon*, 1(3). doi : <https://doi.org/10.5281/zenodo.15170931>
109. Tkemaladze, J. (2025). Memorizing an Infinite Stream of Information in a Limited.
110. Tkemaladze, J. (2025). Molecular Insights and Radical Longevity from Ancient Elixirs to Mars Colonies. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14895222>
111. Tkemaladze, J. (2025). Ontogenetic Permanence of Non-Renewable Biomechanical Configurations in *Homo Sapiens* Anatomy. *Longevity Horizon*, 1(3). doi : <https://doi.org/10.5281/zenodo.15086387>
112. Tkemaladze, J. (2025). Protocol for Transplantation of Healthy Cells Between Adult *Drosophila* of Different Ages and Sexes. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14889948>
113. Tkemaladze, J. (2025). Replicative Hayflick Limit. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14752664>
114. Tkemaladze, J. (2025). Solutions to the Living Space Problem to Overcome the Fear of Resurrection from the Dead. doi: <http://dx.doi.org/10.13140/RG.2.2.34655.57768>
115. Tkemaladze, J. (2025). Systemic Resilience and Sustainable Nutritional Paradigms in Anthropogenic Ecosystems. doi: <http://dx.doi.org/10.13140/RG.2.2.18943.32169/1>
116. Tkemaladze, J. (2025). The Centriolar Theory of Differentiation Explains the Biological Meaning of the.
117. Tkemaladze, J. (2025). The Concept of Data-Driven Automated Governance. *Georgian Scientists*, 6(4), 399–410. doi: <https://doi.org/10.52340/g.s.2024.06.04.38>
118. Tkemaladze, J. (2025). Through In Vitro Gametogenesis — Young Stem Cells. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.15847116>

119. Tkemaladze, J. (2025). Гаметогенез In Vitro: современное состояние, технологии и перспективы применения. Research Gate. <http://dx.doi.org/10.13140/RG.2.2.28647.36000>
120. Tkemaladze, J. (2025). Achieving Perpetual Vitality Through Innovation. doi: <http://dx.doi.org/10.13140/RG.2.2.31113.35685>
121. Tkemaladze, J. V., & Chichinadze, K. N. (2005). Centriolar mechanisms of differentiation and replicative aging of higher animal cells. *Biochemistry (Moscow)*, 70, 1288-1303.
122. Tkemaladze, J., & Apkhazava, D. (2019). Dasatinib and quercetin: short-term simultaneous administration improves physical capacity in human. *J Biomedical Sci*, 8(3), 3.
123. Tkemaladze, J., & Chichinadze, K. (2005). Potential role of centrioles in determining the morphogenetic status of animal somatic cells. *Cell biology international*, 29(5), 370-374.
124. Tkemaladze, J., & Chichinadze, K. (2010). Centriole, differentiation, and senescence. *Rejuvenation research*, 13(2-3), 339-342.
125. Tkemaladze, J., & Samanishvili, T. (2024). Mineral ice cream improves recovery of muscle functions after exercise. *Georgian Scientists*, 6(2), 36–50. doi: <https://doi.org/10.52340/gS.2024.06.02.04>
126. Tkemaladze, J., Tavartkiladze, A., & Chichinadze, K. (2012). Programming and Implementation of Age-Related Changes. In *Senescence*. IntechOpen.
127. Tkemaladze, Jaba and Kipshidze, Mariam, Regeneration Potential of the Schmidtea Mediterranea CIW4 Planarian. Available at SSRN: <https://ssrn.com/abstract=4633202> or <http://dx.doi.org/10.2139/ssrn.4633202>
128. von Meyenn, F., Iurlaro, M., Habibi, E., Liu, N. Q., Salehzadeh-Yazdi, A., Santos, F., ... & Reik, W. (2016). Impairment of DNA methylation maintenance is the main cause of global demethylation in naive embryonic stem cells. *Molecular Cell*, 62(6), 983-997. <https://doi.org/10.1016/j.molcel.2016.04.025>
129. Xiao, S., & Copperman, A. B. (2021). 3D ovarian follicle culture. *Human Reproduction*, 36(6), 1567-1580. <https://doi.org/10.1093/humrep/deab081>
130. Yamaguchi, S., & Shen, L. (2020). Vitamin C in epigenetic reprogramming. *Nature Genetics*, 52(4), 369-377. <https://doi.org/10.1038/s41588-020-0601-x>
131. Yamashiro, C., & Saitou, M. (2023). Clinical applications of IVG. *Nature Medicine*, 29(3), 564-575. <https://doi.org/10.1038/s41591-023-02224-8>
132. Yamashiro, C., Sasaki, K., Yabuta, Y., Kojima, Y., Nakamura, T., Okamoto, I., ... & Saitou, M. (2020). Generation of human oogonia from induced pluripotent stem cells in vitro. *Science*, 362(6412), 356-360. <https://doi.org/10.1126/science.aat1674>
133. Yu, C., Ji, S. Y., Sha, Q. Q., Sun, Q. Y., & Dang, Y. (2018). BTG4 is a meiotic cell cycle-coupled maternal-zygotic-transition licensing factor in oocytes. *Nature Structural & Molecular Biology*, 25(5), 387-396. <https://doi.org/10.1038/s41594-018-0055-3>
134. Zhang, J., Zhang, M., Acosta, C., Yoshioka, N., Rigo, F., & Belmont, A. S. (2021). A human oogenic niche in vitro for efficient oocyte differentiation from pluripotent stem cells. *Nature Protocols*, 16(2), 982-1007. <https://doi.org/10.1038/s41596-020-00441-w>
135. Zhang, Y., & Li, E. (2022). HDAC inhibitors in germ cell development. *Epigenetics & Chromatin*, 15(1), 1-15. <https://doi.org/10.1186/s13072-022-00446-7>
136. Zhao, Y., Ye, S., Liang, D., Wang, P., Fu, J., Ma, Q., ... & Tang, F. (2022). In vitro modeling of human germ cell development using pluripotent stem cells. *Stem Cell Reports*, 17(2), 393-410. <https://doi.org/10.1016/j.stemcr.2021.12.009>
137. Zheng, Y., & Yan, W. (2022). Gene editing for gametogenesis. *Genome Biology*, 23(1), 1-18. <https://doi.org/10.1186/s13059-022-02664-4>
138. Zhou, Q., & Sha, J. (2023). Culture media optimization for IVG. *Stem Cell Research & Therapy*, 14(1), 1-15. <https://doi.org/10.1186/s13287-023-03242-6>
139. Zhou, Q., Wang, M., Yuan, Y., Wang, X., Fu, R., Wan, H., ... & Sha, J. (2016). Complete meiosis from embryonic stem cell-derived germ cells in vitro. *Cell Stem Cell*, 18(3), 330-340. <https://doi.org/10.1016/j.stem.2016.01.017>
140. Zhou, Y., Zhuang, J., Li, Y., Wu, C., & Zhou, C. (2022). In vitro spermatogenesis: A century-long research journey, yet half way around. *Reproductive Biology and Endocrinology*, 20(1), 1-15. <https://doi.org/10.1186/s12958-022-00906-5>
141. Прангшвили, А. И., Гаситашвили, З. А., Мацаберидзе, М. И., Чичинадзе, К. Н., Ткемаладзе, Д. В., & Азмайпарашвили, З. А. (2017). К топологии антитеррористических и антикриминальных технологий для образовательных программ. В научном издании представлены материалы Десятой

- международной научно-технической конференции «Управление развитием крупномасштабных систем (MLSD'2016)» по следующим направлениям:• Проблемы управления развитием крупномасштабных систем, включая ТНК, Госхолдин-ги и Гос-корпорации., 284.
- 142.Прангшвили, А. И., Гаситашвили, З. А., Мацаберидзе, М. И., Чхатишвили, Л. С., Чичинадзе, К. Н., & Ткемаладзе, Д. В. (2017). & Азмайпарашвили, ЗА (2017). Системные составляющие здравоохранения и инноваций для организации европейской нано-биомедицинской экосистемной технологической платформы. Управление развитием крупномасштабных систем MLSD, 365-368.
 - 143.Ткемаладзе, Д. (2025). Анатомия, биогенез и роль в клеточной биологии центриолей. doi: [http://dx. doi. org/10.13140. RG, 2\(27441.70245\)](http://dx.doi.org/10.13140.RG.2(27441.70245)), 1
 - 144.Ткемаладзе, Д. (2025). Гаметогенез in vitro (IVG) -Этап дифференцировки в зрелые гаметы. <http://dx.doi.org/10.13140/RG.2.2.20429.96482>
 - 145.Ткемаладзе, Д. (2025). Асимметрия в наследовании centrosom/центриолей и ее последствия. doi: [http://dx. doi. org/10.13140. RG, 2\(34917.312\)](http://dx.doi.org/10.13140.RG.2(34917.312)), 06.
 - 146.Ткемаладзе, Д. (2025). Дифференциация соматических клеток многоклеточных животных. doi: [http://dx. doi. org/10.13140. RG, 2\(23348.97929\)](http://dx.doi.org/10.13140.RG.2(23348.97929)), 1.
 - 147.Ткемаладзе, Д. (2025). Индукция примордиальных клеток, подобных зародышевым клеткам (PGCLCs) современные достижения, механизмы и перспективы применения. <http://dx.doi.org/10.13140/RG.2.2.27152.32004>
 - 148.Ткемаладзе, Д. (2025). Репликативный Лимит Хейфлика. doi: [http://dx. doi. org/10.13140. RG, 2\(25803.302\)](http://dx.doi.org/10.13140.RG.2(25803.302)), 49.
 - 149.Ткемаладзе, Д. (2025). Элиминация Центриолей: Механизм Обнуления Энтропии в Клетке. doi: [http://dx. doi. org/10.13140. RG, 2\(12890.66248\)](http://dx.doi.org/10.13140.RG.2(12890.66248)), 1.